Palonosetron

Listed in Dosage.

Adult: PO Nausea and vomiting associated w/ cancer chemotherapy 500 mcg 1 hr before therapy. IV Nausea and vomiting associated w/ cancer chemotherapy 250 mcg over 30 sec approx 30 min before therapy. Prophylaxis of postoperative nausea and vomiting 75 mcg over 10 sec before induction of anaesthesia.

Patient w/ history of constipation, intestinal obstruction, history or risk of QT interval prolongation, electrolyte abnormalities. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, somnolence or fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of serotonin syndrome.

Significant: QT prolongation, bradycardia, hypersensitivity reactions (e.g. anaphylaxis). Nervous: Headache, dizziness, somnolence, fatigue, weakness, anxiety, vertigo, flu-like symptoms, insomnia, paresthesia. CV: Nonsustained tachycardia, hypotension, HTN, MI, hot flush. GI: Constipation, diarrhoea, abdominal pain, dyspepsia, dry mouth, hiccups, flatulence, anorexia. Hepatic: Increased serum ALT/AST, bilirubin. Genitourinary: Urinary retention. Endocrine: Hyperkalaemia, electrolyte fluctuations, hyperglycaemia, metabolic acidosis, glycosuria. Musculoskeletal: Arthralgia. Ophthalmologic: Amblyopia. Otic: Tinnitus. Dermatologic: Pruritus, rash, allergic dermatitis. Others: Inj site reaction.
Potentially Fatal: Rarely, serotonin syndrome (e.g. altered mental status, autonomic instability, neuromuscular symptoms).

Decreased therapeutic effect of tramadol.

Supportive Care Therapy / Antiemetics

A04AA05 - palonosetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.